<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00134160</url>
  </required_header>
  <id_info>
    <org_study_id>15-April-2005</org_study_id>
    <nct_id>NCT00134160</nct_id>
  </id_info>
  <brief_title>OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study</brief_title>
  <official_title>The Study Comparing the Incidence of Cardiovascular Events Between High-dose ARB Monotherapy and Combination Therapy With ARB and Calcium Channel Blocker in Japanese Elderly Hypertensive Patients at High Cardiovascular Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OSCAR Study</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Japan Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>OSCAR Study</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether high-dose angiotensin II receptor blocker&#xD;
      (ARB) monotherapy or combination therapy with ARB and calcium channel blockers is more&#xD;
      effective in reducing the incidence of cardiovascular events in Japanese elderly high-risk&#xD;
      hypertensive patients not adequately controlled by standard dose ARB alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypertension is one of the major risk factors of cardiovascular diseases. It is also&#xD;
      important for elderly hypertensive patients to strictly reduce their blood pressures to&#xD;
      prevent cardiovascular events. Although angiotensin II receptor blockers (ARBs) are&#xD;
      increasingly used in antihypertensive treatment recently, few studies have been performed in&#xD;
      Japan to assess the difference between high-dose ARB monotherapy and combination therapy of&#xD;
      ARB with calcium channel blocker (CCB) in prevention of cardiovascular diseases for patients&#xD;
      whose blood pressure is not well controlled by ARB monotherapy. OSCAR-study is a multicenter,&#xD;
      active-controlled, 2-arm parallel group comparison, prospective randomized open blinded&#xD;
      end-point (PROBE) design study. The dose administered is olmesartan medoxomil 20mg/day as ARB&#xD;
      monotherapy in the 'Step 1' period. If the blood pressure is not adequately controlled and&#xD;
      treatment is well tolerated then the dose is changed to olmesartan medoxomil 40mg/day in the&#xD;
      high-dose ARB monotherapy group, or olmesartan medoxomil 20mg/day and a CCB in the&#xD;
      combination therapy group in the 'Step 2' period. At least 500 patients will be enrolled in&#xD;
      each group, and the follow-up duration will be 3 years. The primary objective is to compare&#xD;
      the incidence of a composite of fatal and non-fatal cardiovascular events, and all cause&#xD;
      mortality between the two treatment groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A composite of fatal and non-fatal cardiovascular events: Cerebrovascular events (cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, stroke of undetermined etiology and transient ischemic attack)</measure>
    <time_frame>36 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Coronary events (sudden death, myocardial infarction, angina pectoris, asymptomatic myocardial ischemia)</measure>
    <time_frame>36 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart failure</measure>
    <time_frame>36 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vascular events (aortic aneurysm, aortic dissection, and arteriosclerotic diseases)</measure>
    <time_frame>36 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Diabetic complications (nephropathy, retinopathy and neuropathy)</measure>
    <time_frame>36 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal dysfunction (doubling of serum creatinine, end stage renal diseases)</measure>
    <time_frame>36 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>36 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of each cardiovascular event</measure>
    <time_frame>36 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure change (systolic blood pressure [SBP], diastolic blood pressure [DBP], mean blood pressure [MBP]) at every observation point in the follow-up period</measure>
    <time_frame>36 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events other than primary outcome events</measure>
    <time_frame>36 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Hypertension</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High-dose ARB monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Combination therapy of ARB with Calcium Channel Blocker</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan medoxomil</intervention_name>
    <description>Olmesartan medoxomil 40mg/Day</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium channel blockers (amlodipine, azelnidipine)</intervention_name>
    <description>Olmesartan medoxomil 20mg/Day with Calcium channel blockers (amlodipine or azelnidipine)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Outpatients aged 65 years or older, and less than 85 years (at the time of informed&#xD;
             consent), regardless of sex&#xD;
&#xD;
          -  Current antihypertensive treatment with monotherapy&#xD;
&#xD;
          -  SBP ≥ 140mmHg or DBP ≥ 90mmHg in a sitting position on two measurements on two clinic&#xD;
             visits&#xD;
&#xD;
          -  At least one of the following risk factors:&#xD;
&#xD;
               -  Diabetes mellitus Type 2;&#xD;
&#xD;
               -  History of cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, or&#xD;
                  transient ischemic attack (more than 6 months before giving informed consent);&#xD;
&#xD;
               -  Diagnosis of asymptomatic cerebrovascular disease;&#xD;
&#xD;
               -  History of myocardial infarction (more than 6 months before giving informed&#xD;
                  consent);&#xD;
&#xD;
               -  Diagnosis of angina pectoris or heart failure (New York Heart Association [NYHA]&#xD;
                  functional classification I or II);&#xD;
&#xD;
               -  Diagnosis of left ventricular hypertrophy (thickness of the wall of&#xD;
                  interventricular septum ≥ 12mm on echocardiography or Sv1+Rv5 ≥ 35mm on&#xD;
                  electrocardiography before informed consent);&#xD;
&#xD;
               -  Diagnosis of aortic aneurysm;&#xD;
&#xD;
               -  History of aortic dissection (more than 6 months before giving informed consent);&#xD;
&#xD;
               -  Diagnosis of arteriosclerotic peripheral arterial obstruction (Fontaine&#xD;
                  classification from 2 to 4);&#xD;
&#xD;
               -  Serum creatinine: 1.2-2.5mg/dL (male); 1.0-2.5mg/dL (female);&#xD;
&#xD;
               -  Proteinuria: ≥ +1 (or ≥ 0.3g/g･Cr. estimated from 24-hour urine collection or&#xD;
                  random urinary protein corrected by urine creatinine).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Secondary hypertension or malignant hypertension&#xD;
&#xD;
          -  Heart failure (NYHA functional classification III or IV)&#xD;
&#xD;
          -  Required treatment for malignant tumor&#xD;
&#xD;
          -  Serious liver or renal dysfunction (serum creatinine &gt; 2.5mg/dL or with dialysis&#xD;
             treatment)&#xD;
&#xD;
          -  Not appropriate for change to the test drugs from current therapy for hypertension or&#xD;
             coronary diseases (i.e. calcium channel blockers, β-blockers, thiazide diuretics,&#xD;
             etc.)&#xD;
&#xD;
          -  History of serious adverse drug reactions to angiotensin II receptor blockers or&#xD;
             calcium channel blockers&#xD;
&#xD;
          -  Patients with other serious reasons (i.e. illness, significant abnormalities, etc.)&#xD;
             that investigators judge inappropriate for the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kikuo Arakawa, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Emeritus Professor Fukuoka University, Fukuoka, Japan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiovascular Medicine Graduate School of Medical Science Kumamoto University</name>
      <address>
        <city>1-1-1 Honjyo, Kumamoto-City</city>
        <state>Kumamoto</state>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSCAR-Study Data Center</name>
      <address>
        <city>ShinjukuParkTower30FN, 3-7-1 Nishi-Shinjuku, Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>163-1030</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <study_first_submitted>August 22, 2005</study_first_submitted>
  <study_first_submitted_qc>August 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2005</study_first_posted>
  <last_update_submitted>October 3, 2010</last_update_submitted>
  <last_update_submitted_qc>October 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>Ogawa Hisao</name_title>
    <organization>Kumamoto University Graduate School of Medical Science</organization>
  </responsible_party>
  <keyword>Aged</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Angiotensin II Type 1 Receptor Blockers</keyword>
  <keyword>Calcium Channel Blockers</keyword>
  <keyword>Combination Drug Therapy</keyword>
  <keyword>Diabetes Mellitus Type 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
    <mesh_term>Calcium Channel Blockers</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

